Literature DB >> 18022109

Side effect profile and tolerability of adenosine myocardial perfusion scintigraphy in patients with mild asthma or chronic obstructive pulmonary disease.

Eliana Reyes1, Chee Y Loong, Kshama Wechalekar, Katherine Latus, Constantinos Anagnostopoulos, S Richard Underwood.   

Abstract

BACKGROUND: Adenosine may cause bronchoconstriction in subjects with asthma or chronic obstructive pulmonary disease (COPD). Recent evidence suggests that this effect may be dependent on the severity of disease. This study investigates the tolerability of adenosine stress in patients with mild asthma or COPD undergoing myocardial perfusion scintigraphy. METHODS AND
RESULTS: In this case-control study patients with known or suspected mild asthma or COPD were pretreated with an inhaled beta(2)-adrenergic agonist and adenosine titrated up to the maximal dose of 140 microg x kg(-1) x min(-1) over a period of 6 minutes. The occurrence of side effects and test tolerability were compared between the airway disease group and 72 control subjects. Of 1261 patients, 124 had known or suspected airway disease; of these, 72 (58%) were suitable for adenosine stress. The proportion of tests completed as per protocol in the asthma/COPD group was similar to that of control subjects (93% vs 100%, P = .06). Dyspnea (n = 38 [53%] in asthma/COPD group vs n = 25 [35%] in control group, P = .03) and chest pain (n = 14 [19%] in asthma/COPD group vs n = 16 [22%] in control group, P = .7) were the most common side effects, and these were mostly mild and well tolerated. Bronchospasm occurred in 5 patients with asthma/COPD but reverted shortly after discontinuation of the adenosine infusion. Aminophylline was not required in any case.
CONCLUSIONS: A stepwise 6-minute adenosine infusion with prophylactic beta(2)-adrenergic agonist is safe and well tolerated in patients with mild asthma or COPD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18022109     DOI: 10.1016/j.nuclcard.2007.07.013

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  26 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Is the dyspnea during adenosine cardiac stress test caused by bronchospasm?

Authors:  K K Balan; M Critchley
Journal:  Am Heart J       Date:  2001-07       Impact factor: 4.749

3.  Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging.

Authors:  Robert C Hendel; Timothy M Bateman; Manuel D Cerqueira; Ami E Iskandrian; Jeffrey A Leppo; Brent Blackburn; John J Mahmarian
Journal:  J Am Coll Cardiol       Date:  2005-11-09       Impact factor: 24.094

4.  PC(20) adenosine 5'-monophosphate is more closely associated with airway inflammation in asthma than PC(20) methacholine.

Authors:  M Van Den Berge; R J Meijer; H A Kerstjens; D M de Reus; G H Koëter; H F Kauffman; D S Postma
Journal:  Am J Respir Crit Care Med       Date:  2001-06       Impact factor: 21.405

5.  Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects.

Authors:  M J Cushley; A E Tattersfield; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

6.  Bronchial asthma causing symptoms suggestive of angina pectoris.

Authors:  D Kiss; W Veegh; D Schragel; C Bachl; C Stöllberger; K Sertl
Journal:  Eur Respir J       Date:  2003-03       Impact factor: 16.671

Review 7.  Dobutamine stress myocardial perfusion imaging.

Authors:  M L Geleijnse; A Elhendy; P M Fioretti; J R Roelandt
Journal:  J Am Coll Cardiol       Date:  2000-12       Impact factor: 24.094

8.  A(2B) adenosine receptors increase cytokine release by bronchial smooth muscle cells.

Authors:  Hongyan Zhong; Luiz Belardinelli; Tenning Maa; Igor Feoktistov; Italo Biaggioni; Dewan Zeng
Journal:  Am J Respir Cell Mol Biol       Date:  2003-07-10       Impact factor: 6.914

9.  Influence of infused adenosine on bronchial tone and bronchial reactivity in asthma.

Authors:  K Larsson; A Sollevi
Journal:  Chest       Date:  1988-02       Impact factor: 9.410

10.  Comparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogs.

Authors:  Gong Zhao; Axel Linke; Xiaobin Xu; Manuel Ochoa; Francis Belloni; Luiz Belardinelli; Thomas H Hintze
Journal:  J Pharmacol Exp Ther       Date:  2003-09-03       Impact factor: 4.030

View more
  6 in total

1.  Development of asystole requiring cardiac resuscitation after the administration of regadenoson in a patient with pulmonary fibrosis receiving n-acetylcysteine.

Authors:  Erin C Grady; John T Barron; Robert H Wagner
Journal:  J Nucl Cardiol       Date:  2011-05       Impact factor: 5.952

2.  Adenosine stress myocardial perfusion imaging in octogenarians: Safety, tolerability, and long-term prognostic implications of hemodynamic response and SPECT-related variables.

Authors:  Athanasios Katsikis; Athanasios Theodorakos; Spyridon Papaioannou; Antonios Kalkinis; Genovefa Kolovou; Konstantinos Konstantinou; Maria Koutelou
Journal:  J Nucl Cardiol       Date:  2017-04-26       Impact factor: 5.952

3.  ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers.

Authors:  Milena J Henzlova; W Lane Duvall; Andrew J Einstein; Mark I Travin; Hein J Verberne
Journal:  J Nucl Cardiol       Date:  2016-06       Impact factor: 5.952

4.  Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients.

Authors:  Zehra Husain; Gurunanthan Palani; Rafael Cabrera; Aarthee S Karthikeyan; Sunitha Dhanalakota; Suba Pathmanathan; Gordon Jacobsen; Karthik Ananthasubramaniam
Journal:  Int J Cardiovasc Imaging       Date:  2011-12-27       Impact factor: 2.357

5.  Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial).

Authors:  Gregory S Thomas; Bruce R Tammelin; George L Schiffman; Rudy Marquez; Deborah L Rice; Douglas Milikien; Vandana Mathur
Journal:  J Nucl Cardiol       Date:  2008-04-14       Impact factor: 5.952

6.  Current awareness: pharmacoepidemiology and drug safety.

Authors: 
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-06       Impact factor: 2.890

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.